Author Interviews, Pulmonary Disease / 12.10.2015
Tyrosine Kinase Inhibitor Slows Progression of Idiopathic Pulmonary Fibrosis
MedicalResearch.com Interview with:
Eric Stephen White MD
Associate Professor of Medicine and Director of Translational Interstitial Lung Disease Research, Pulmonary and Critical Care Medicine
University of Michigan Health System
Medical Research: What is the background for this study? What are the main findings?
Dr. White: The data presented at the European Respiratory Society (ERS) International Congress 2015 provide additional insights into OFEV® (nintedanib), including safety and efficacy over approximately two years. The results show no relevant changes in the safety and tolerability of OFEV. The results also suggest that treatment has a long-term effect (approximately two years) on slowing disease progression across both pivotal and open-label trials (as measured by annual rate of forced vital capacity [FVC] decline). This ongoing study, INPULSIS™-ON, which is an open-label extension trial, is important because Idiopathic Pulmonary Fibrosis (IPF) is a progressive disease that may require ongoing treatment.
(more…)